Dr. Dawn Bell is a global, strategic, biopharmaceutical executive (NYSE: NVS), Board Director, GM, and start-up CEO. Working in large pharma, mid-sized, and start-up companies, she has developed and launched 12+ innovative medicines across 8 therapeutic areas, including the blockbuster Entresto where she led global development, registration and launch in major markets. She provides companies and boards valuable insights on value creation, fundraising, and business development.

Dawn is energized by working with and advising founders and start-up CEO’s. She is a valued mentor in the Creative Destruction Lab (Toronto) and Executive Council member in EIT Health’s Gold Track Program (Germany), contributing to companies raising €250M and achieving four exits, worth €1B+ in her three years on the Council. She serves as a board advisor to two privately held, venture-backed drug discovery companies and Board Director for The Metabolomics Innovation Center, a nationally funded research facility based in Alberta, Canada.

At Novartis, Dawn has held leadership roles across strategy, medical affairs, business development, and global drug development. Currently, she is VP and Global Development Head of Strategic Partnerships where she leads business development and portfolio strategy for whitespace opportunities. Preceding Novartis, Dawn was CEO/co-founder of Cool-Bio, a private, pre-clinical stage biotech. Prior to joining the industry, Dawn was a tenured Associate Professor of Pharmacy at West Virginia University. She earned her Doctor of Pharmacy degree from the University of Florida and was a Genentech Cardiovascular Genomics Fellow.